BPI-16350
Phase 1Small molecule
BPI-16350 is one of 40 small molecule programs targeting Advanced Solid Tumor. It is currently in Phase 1.
1
Indications
3
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Advanced Solid Tumor
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Mekinist
NovartisPhase 2
Fludara
SanofiPhase 2
Tafinlar
NovartisPhase 2
Paraplatin
AAvyxa
Phase 2
Alimta
SShawn Eagle
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Zytiga
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BPI-16350. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBetta Pharmaceuticals Co., Ltd.